GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner

Park, Mi So; Yang, A-Yeong; Lee, Jae Eun; Kim, Seon‐Kyu; Roe, Jae‐Seok; Park, Min-Seok; Oh, Myung Jin; An, Hyun Joo; Kim, Miyoung

doi:10.1016/j.canlet.2021.08.015

Cited by 21 publications

(14 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other O‐glycoproteins, including Amyloid precursor protein ( APP ) or Tau, are considered to become biomarkers for early diagnosis of Alzheimer's Disease (AD) [107–110]. GALNT3 has been also recognized as a valuable biomarker for poor prognosis and early recurrence in patients with completely resected lung cancer [111]. Recent advances in the field of O‐glycosylation have led to the recognition that abnormal expression of Tn antigen is associated with rheumatoid arthritis [112] and cancer [113] (Figures 1D and S2).…”

Section: The Role Of O‐glycosylation In Health and Diseasesmentioning

confidence: 99%

Recent advances in demystifying O‐glycosylation in health and disease

Zhang

Yue

et al. 2022

Proteomics

View full text Add to dashboard Cite

O-Glycosylation is one of the most common protein post-translational modifications (PTM) and plays an essential role in the pathophysiology of diseases. However, the complexity of O-glycosylation and the lack of specific enzymes for the processing of O-glycans and their O-glycopeptides make O-glycosylation analysis challenging. Recently, research on O-glycosylation has received attention owing to technological innovation and emerging O-glycoproteases. Several serine/threonine endoproteases have been found to specifically cleave O-glycosylated serine or threonine, allowing for the systematic analysis of O-glycoproteins. In this review, we first assessed the field of protein O-glycosylation over the past decade and used bibliometric analysis to identify keywords and emerging trends. We then summarized recent advances in O-glycosylation, covering several aspects: O-glycan release, site-specific elucidation of intact O-glycopeptides, identification of O-glycosites, characterization of different O-glycoproteases, mass spectrometry (MS) fragmentation methods for site-specific O-glycosylation assignment, and O-glycosylation data analysis. Finally, the role of O-glycosylation in health and disease was discussed.

show abstract

Section: The Role Of O‐glycosylation In Health and Diseasesmentioning

confidence: 99%

Recent advances in demystifying O‐glycosylation in health and disease

Zhang

Yue

et al. 2022

Proteomics

View full text Add to dashboard Cite

show abstract

“…Similarly, CIGB-300 is an anti-casein kinase 2 (CK2) peptide that inhibits the expression of Notch and VEGF in ECs by regulating the Notch/VEGF signaling pathway ( 62 ). Polypeptide N-acetyl-galactosaminyltransferases (GALNTs) inhibits angiogenesis and invasion of myeloid-derived suppressor cells (MDSCs) by inhibiting the c-Met/AKT signaling pathway, preventing the generation of optimal TME and inhibiting lung cancer progression ( 63 ).…”

Section: Novel Angiogenic Regulators In Lung Cancer Treatmentmentioning

confidence: 99%

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

Lin

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer growth is dependent on angiogenesis. In recent years, angiogenesis inhibitors have attracted more and more attention as potential lung cancer treatments. Current anti-angiogenic drugs targeting VEGF or receptor tyrosine kinases mainly inhibit tumor growth by reducing angiogenesis and blocking the energy supply of lung cancer cells. However, these drugs have limited efficiency, raising concerns about limited scope of action and mechanisms of patient resistance to existing drugs. Therefore, current basic research on angiogenic regulators has focused more on screening carcinogenic/anticancer genes, miRNAs, lncRNAs, proteins and other biomolecules capable of regulating the expression of specific targets in angiogenesis signaling pathways. In addition, new uses for existing drugs and new drug delivery systems have received increasing attention. In our article, we analyze the application status and research hotspots of angiogenesis inhibitors in lung cancer treatment as a reference for subsequent mechanistic research and drug development.

show abstract

“…To date, 20 GALNT family members (from GALNT1 to GALNT20) have been identified in the human genome. GALNTs play critical roles in numerous physiological and pathological processes [ 10 – 12 ]. However, a comprehensive analysis of GALNTs in NSCLC has yet to be conducted.…”

Section: Introductionmentioning

confidence: 99%

The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer

Tian

Leng

et al. 2022

Cell Mol Biol Lett

View full text Add to dashboard Cite

Background N-Acetylgalactosaminyltransferases (GALNTs), the enzymes that initiate mucin-type O-glycosylation, are closely associated with tumor occurrence and progression. However, a comprehensive analysis of GALNTs in non-small cell lung cancer (NSCLC) is lacking. Methods The expression profiles and prognostic values of the GALNT family members in NSCLC were analyzed using publicly available databases. Gain- and loss-of-function experiments were applied to assess the biological function of GALNT2 in NSCLC. High-throughput sequencing and bioinformatics approaches were employed to uncover the regulatory mechanism of GALNT2. Results Among the family members of GALNTs, only GALNT2 was frequently overexpressed in NSCLC tissues and was positively correlated with poor prognosis. In vitro assays showed that GALNT2 knockdown repressed NSCLC cell proliferation, migration, and invasion, but induced apoptosis and cell cycle arrest. Correspondently, GALNT2 overexpression exerted the opposite effects. In vivo experiments demonstrated that knockdown of GALNT2 restrained tumor formation in nude mice. Mechanistic investigations revealed that GALNT2 modified the O-glycosylation of ITGA5 and affected the activation of the PI3K/Akt and MAPK/ERK pathways. Further studies showed that miR-30d was a negative regulator of GALNT2. Conclusions These findings suggest that GALNT2 is an oncogene in NSCLC and has the potential as a target for NSCLC therapy.

show abstract

GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner

Cited by 21 publications

References 63 publications

Recent advances in demystifying O‐glycosylation in health and disease

Recent advances in demystifying O‐glycosylation in health and disease

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer

Contact Info

Product

Resources

About